Trials / Completed
CompletedNCT00918814
Dose Ranging and Dose Frequency of LIPO-102
A Dose-Ranging and Dose Frequency Study Evaluating the Safety and Efficacy of LIPO-102 for the Reduction of Abdominal Subcutaneous Adipose Tissue
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- Neothetics, Inc · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
Dose Ranging and Dose Frequency of LIPO-102
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LIPO-102 | Subcutaneous Injection |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2009-06-01
- Primary completion
- 2010-02-01
- Completion
- 2010-02-01
- First posted
- 2009-06-11
- Last updated
- 2015-03-06
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00918814. Inclusion in this directory is not an endorsement.